Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 12/20 | 0.52 |
| ▸ | BPTF | Q12830 | 1/20 | 0.52 |
| ▸ | CCNK | O75909 | 3/20 | 0.48 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.48 |
| ▸ | IL1B | P01584 | 5/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20145228 | 0.82 | IL1B (0.54) | KAT2BBPTFCCNKCDK12IL1B | |
| SCHEMBL20145078 | 0.80 | IL1B (0.46) | KAT2BBPTFCCNKCDK12IL1B | |
| SCHEMBL31333152 | 0.80 | KAT2B (0.49) | KAT2BBPTFCCNKCDK12IL1B | |
| SCHEMBL20145184 | 0.78 | IL1B (0.42) | KAT2BBPTFIL1BNLRP3 | |
| SCHEMBL22654959 | 0.77 | IL1B (0.61) | KAT2BBPTFIL1BNLRP3 | |
| SCHEMBL22654958 | 0.77 | IL1B (0.61) | KAT2BBPTFIL1BNLRP3 | |
| SCHEMBL22655979 | 0.77 | IL1B (0.61) | KAT2BBPTFIL1BNLRP3 | |
| SCHEMBL23081193 | 0.76 | BTK (0.46) | KAT2BBPTFCCNKCDK12IL1B | |
| SCHEMBL23081051 | 0.76 | BTK (0.46) | KAT2BBPTFCCNKCDK12IL1B | |
| SCHEMBL22895690 | 0.75 | CCNK (0.54) | CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970207-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-16 | — | — | EP | disclosed |